Puma Biotechnology Inc. (PBYI) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Puma Biotechnology Inc. (PBYI)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

3.07

-0.02 (-0.65%)

At close: Jan 15, 2025, 12:45 PM

undefined% (undefined)

Bid	3.06
Market Cap	150.66M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.47
PE Ratio (ttm)	6.53
Forward PE	n/a
Analyst	Buy

Ask	3.07
Volume	525,883
Avg. Volume (20D)	567,470
Open	3.16
Previous Close	3.09
Day's Range	2.96 - 3.18
52-Week Range	2.23 - 7.73
Beta	undefined

About PBYI

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advance...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 24, 2012

Employees 185

Stock Exchange NASDAQ

Ticker Symbol PBYI

Website https://www.pumabiotechnology.com

Analyst Forecast

According to 1 analyst ratings, the average rating for PBYI stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 128.08% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Puma Biotechnology Inc. is scheduled to release its earnings on Feb 27, 2025, during market hours.
Analysts project revenue of $52.50M, reflecting a -27.29% YoY shrinking and earnings per share of 0.14, making a -54.84% decrease YoY.

Why Price Moved

10 months ago · Source

-5.76%

Puma Biotechnology shares are trading lower after ... Unlock content with Pro Subscription

News

1 week ago · zacks.com

Best Momentum Stocks to Buy for January 6th

NRXP, PDEX and PBYI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 6, 2024.

1 week ago · zacks.com

Best Value Stocks to Buy for January 6th

AHT, PBYI and CWD made it to the Zacks Rank #1 (Strong Buy) value stocks list on January 6, 2024.

1 week ago · businesswire.com

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on January 2, 2025, the Compensation Committee of Puma's Board of Directors approved ...

2 weeks ago · zacks.com

All You Need to Know About Puma Biotech (PBYI) Rating Upgrade to Strong Buy

Puma Biotech (PBYI) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 weeks ago · zacks.com

Is Puma Biotechnology (PBYI) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

2 weeks ago · zacks.com

Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why

Sales of PBYI's sole-marketed drug, Nerlynx exceeded management's expectations in the third quarter. Also, the acquisition of alisertib holds promise.

3 weeks ago · zacks.com

Best Momentum Stocks to Buy for December 24th

PBYI, DDS and NJR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 24, 2024.

3 weeks ago · zacks.com

New Strong Buy Stocks for December 24th

FTI, NRXP, PBYI, POWL and VMEO have been added to the Zacks Rank #1 (Strong Buy) List on December 24, 2024.

3 weeks ago · zacks.com

Best Value Stocks to Buy for December 24th

PBYI, DDS and PINC made it to the Zacks Rank #1 (Strong Buy) value stocks list on December 24, 2024.

3 weeks ago · businesswire.com

Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

LOS ANGELES--(BUSINESS WIRE)--NCCN Guidelines for Cervical Cancer now include Puma's neratinib monotherapy for 2nd line or later use in patients with HER2-mutated tumors, Cat. 2A.

1 month ago · seekingalpha.com

Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward

Puma Biotechnology focuses on expanding neratinib sales and developing alisertib for breast and lung cancers, despite recent stock declines. Neratinib sales are stagnant, but the company remains stabl...

1 month ago · zacks.com

Should Value Investors Buy Puma Biotechnology (PBYI) Stock?

1 month ago · zacks.com

PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer

Puma Biotechnology starts the phase II ALISCA-Breast1 study on alisertib for treating hormone receptor-positive, HER2-negative metastatic breast cancer.

2 months ago · zacks.com

PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up

Puma Biotechnology beats third-quarter 2024 estimates for both the top and the bottom lines. The company updates its 2024 financial guidance.

2 months ago · seekingalpha.com

Puma Biotechnology, Inc. (PBYI) Q3 2024 Earnings Conference Call Transcript

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - CEO, President and Cha...

2 months ago · zacks.com

Puma Biotech (PBYI) Q3 Earnings and Revenues Surpass Estimates

Puma Biotech (PBYI) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.17 per share a year ago.